IBC Speakers Predict Reimbursement Woes For Personalized Diagnostic Tests
This article was originally published in The Gray Sheet
Executive Summary
Variation in local Medicare coverage policies for Genentech's Herceptin demonstrates the difficulty CMS will face as predictive molecular diagnostic test use becomes more prevalent, according to Covance VP-Health Economics and Outcome Services David Parker
You may also be interested in...
FDA Pharmacogenetic Regulation: Three Guidances, Fall Workshop
FDA is planning to issue three guidances on pharmaco-genomics over the next 18 months
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.